Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study.

Becker, Christian M et al.·Human reproduction (Oxford·2024·
RPEP-078332024RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Key Numbers

How They Did This

Why This Research Matters

What This Study Doesn't Tell Us

Trust & Context

Original Title:
Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study.
Published In:
Human reproduction (Oxford, England), 39(3), 526-537 (2024)
Database ID:
RPEP-07833

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-07833·https://rethinkpeptides.com/research/RPEP-07833

APA

Becker, Christian M; Johnson, Neil P; As-Sanie, Sawsan; Arjona Ferreira, Juan C; Abrao, Mauricio S; Wilk, Krzysztof; Imm, So Jung; Mathur, Vandana; Perry, Julie S; Wagman, Rachel B; Giudice, Linda C. (2024). Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study.. Human reproduction (Oxford, England), 39(3), 526-537. https://doi.org/10.1093/humrep/dead263

MLA

Becker, Christian M, et al. "Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study.." Human reproduction (Oxford, 2024. https://doi.org/10.1093/humrep/dead263

RethinkPeptides

RethinkPeptides Research Database. "Two-year efficacy and safety of relugolix combination therap..." RPEP-07833. Retrieved from https://rethinkpeptides.com/research/becker-2024-twoyear-efficacy-and-safety

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.